&nbsp;

DerekMcNally.jpg

Dec 1969

Données sur l’utilisation des médicaments biosimilaires en oncologie

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Status: Current
ID: PET 2023-1

Nov 2023

Regimen

DOST(MNT); CRBPPACL+DOST

Cancer Type:

Gynecologic,

Endometrial

Intent: Adjuvant, Curative, Palliative

Funding:

New Drug Funding Program

Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

EPCO; EPCO(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

High Cost Therapy Funding Program

Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

, Collapse Show fewer tags

Drugs Used:

epcoritamab

... Show more tags

Quick Link(s):

Regimen Monograph

Document

dapColorectal15Feb2024.xml

Dec 1969

Document

dapColorectal15Feb2024.html

Dec 1969

Document

dapProstate15Feb2024.xml

Dec 1969

Document

dapProstate15Feb2024.html

Dec 1969

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2023

Status: Current
Version: PET 2023-2

Dec 1969

Document